Genexine, Inc. 095700.KQ Stock
Genexine, Inc. Price Chart
Genexine, Inc. 095700.KQ Financial and Trading Overview
| Genexine, Inc. stock price | 7110 KRW |
| Previous Close | 11030 KRW |
| Open | 11050 KRW |
| Bid | 10440 KRW x 0 |
| Ask | 10450 KRW x 0 |
| Day's Range | 10330 - 11220 KRW |
| 52 Week Range | 10330 - 27423.08 KRW |
| Volume | 780.56K KRW |
| Avg. Volume | 319.98K KRW |
| Market Cap | 216.41B KRW |
| Beta (5Y Monthly) | 0.898721 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 KRW |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
095700.KQ Valuation Measures
| Enterprise Value | 549.41B KRW |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 13.690571 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 34.757 |
| Enterprise Value/EBITDA | -18.396 |
Trading Information
Genexine, Inc. Stock Price History
| Beta (5Y Monthly) | 0.898721 |
| 52-Week Change | -54.83% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 27423.08 KRW |
| 52 Week Low | 10330 KRW |
| 50-Day Moving Average | 12428.6 KRW |
| 200-Day Moving Average | 15384.89 KRW |
095700.KQ Share Statistics
| Avg. Volume (3 month) | 319.98K KRW |
| Avg. Daily Volume (10-Days) | 351.01K KRW |
| Shares Outstanding | 20.55M |
| Float | 25.69M |
| Short Ratio | N/A |
| % Held by Insiders | 17.03% |
| % Held by Institutions | 6.97% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | N/A |
| Trailing Annual Dividend Yield | N/A |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor | 1.3:1 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2021 |
| Most Recent Quarter (mrq) | September 30, 2022 |
| Next Fiscal Year End | December 31, 2022 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -216.94% |
| Gross Margin | 70.05% |
| EBITDA Margin | -188.93% |
Management Effectiveness
| Return on Assets (ttm) | -3.58% |
| Return on Equity (ttm) | -10.13% |
Income Statement
| Revenue (ttm) | 15.81B KRW |
| Revenue Per Share (ttm) | 484.85 KRW |
| Quarterly Revenue Growth (yoy) | 867.80% |
| Gross Profit (ttm) | 30.74B KRW |
| EBITDA | -29865971712 KRW |
| Net Income Avi to Common (ttm) | -50242834432 KRW |
| Diluted EPS (ttm) | N/A |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 25.06B KRW |
| Total Cash Per Share (mrq) | 766.54 KRW |
| Total Debt (mrq) | 77.79B KRW |
| Total Debt/Equity (mrq) | 23.03 KRW |
| Current Ratio (mrq) | 1.446 |
| Book Value Per Share (mrq) | N/A |
Cash Flow Statement
| Operating Cash Flow (ttm) | -25296881664 KRW |
| Levered Free Cash Flow (ttm) | -85938683904 KRW |
Profile of Genexine, Inc.
| Country | South Korea |
| State | N/A |
| City | Seongnam |
| Address | Korea Bio Park Building B |
| ZIP | 13488 |
| Phone | 82 3 1628 3200 |
| Website | https://www.genexine.com |
| Industry | |
| Sector(s) | |
| Full Time Employees | 109 |
Genexine, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of immunotherapeutics and long-acting biologics in South Korea. It develops hyFc platform, a proprietary technology designed to drive the discovery of various differentiated agonistic protein therapeutics; and the Immune Enhancing Technology, a therapeutic DNA vaccine technology. The company's product pipeline includes GX-H9, which is in Phase II clinical trials for the treatment of adult and pediatric growth hormone deficiency; GX-E2, which is in Phase II clinical trials for the treatment of induced anemia; GX-G3, which is in Phase II clinical trials to treat neutropenia; and GX-G6 that is in Phase I clinical trials for the treatment of diabetes. It is also developing GX-188E that is in Phase II clinical trials in combination with KEYTRUDA for the treatment of cervical cancer. Genexine, Inc. has a co-development partnership with Binex Co. Ltd. to develop COVID-19 vaccine. The company was formerly known as Genexine Co., Ltd. and changed its name to Genexine, Inc. in March 2013. Genexine, Inc. was founded in 1999 and is based in Seongnam, South Korea.
Q&A For Genexine, Inc. Stock
What is a current 095700.KQ stock price?
Genexine, Inc. 095700.KQ stock price today per share is 7110 KRW.
How to purchase Genexine, Inc. stock?
You can buy 095700.KQ shares on the KOSDAQ exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Genexine, Inc.?
The stock symbol or ticker of Genexine, Inc. is 095700.KQ.
How many shares does Genexine, Inc. have in circulation?
The max supply of Genexine, Inc. shares is 41.45M.
What is Genexine, Inc. Price to Earnings Ratio (PE Ratio)?
Genexine, Inc. PE Ratio is now.
What was Genexine, Inc. earnings per share over the trailing 12 months (TTM)?
Genexine, Inc. EPS is 0 KRW over the trailing 12 months.